$43.800
+0.692 (+1.58%)Zum Schluss
VCYT-News
VCYT-Events
Veracyte to Present New Findings on Prostate Cancer at ASTRO Annual Meeting
Veracyte announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology, ASTRO, Annual Meeting. The trial evaluated dose-escalated radiation with or without short-term androgen deprivation therapy, ADT, in men with intermediate-risk prostate cancer. The analysis showed that the Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence. Key study findings: The treatment-by-Decipher interaction for distant metastasis was statistically significant; Among patients with intermediate/high Decipher scores, adding short-term ADT was associated with an 8% absolute reduction in distant metastasis at 10 years; Among the 44% of patients with low Decipher scores, the absolute difference in 10-year distant metastasis was 1 percentage point and was not statistically significant.
Veracyte Acquires Convergent Genomics for $150M
Veracyte announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics' UroAmp platform, including its proprietary urinary tumor DNA technology, to Veracyte's product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer, including therapy-response monitoring and post-treatment surveillance. The acquisition includes $150M in upfront cash consideration and up to $30M in additional cash consideration tied to key milestones related to UroAmp reimbursement efforts. Veracyte contemplated the ongoing operating expenses of Convergent in its previously provided 2026 adjusted EBITDA guidance and is not updating such guidance at this time.
Veracyte Shares Drop 24.1% to $45.37
Veracyte is down -24.1%, or -$14.41 to $45.37.
Apple Shares Face Worst Post-Earnings Drop in 13 Years, $460B Wipeout
The major averages were somewhat higher near noon as traders weighed earnings from Apple and Amazon. While Amazon was trading higher on its quarterly beat, Apple is on pace for a $460B wipeout as its shares are seeing the worst post-earnings drop in 13 years. The sharp losses come after the iPhone maker provided a lower-than-expected revenue outlook for Q4 in the face of foreign exchange issues and supply constraints.The combination of a patient Fed and softer inflation has helped support risk assets, although expectations for future rate moves remain highly sensitive to incoming economic data.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q3 results butfor Q4 revenue growth amid foreign exchange issues and supply constraintsAmazonreported, with AWS net sales rising to $42.23BChevronreported better-than-expected Q2 earnings and revenue, with the company adding that it reportedExxon MobilreportedRedditreported better-than-expected Q2 results and provided2. WALL STREET CALLS:Benchmark and BTIGRobloxto Sell following quarterly resultsPiper Sandler and Cantor FitzgeraldReplimuneto Overweight following a postive FDA panel vote supporting RP1 approvalArgusBoston Scientificto HoldGuggenheimQuanta Servicesto BuyBMO CapitalNextpowerto Outperform3. AROUND THE WEB:Chimeis planning to cut about 10% of its workforce, or 150 employees, to capitalize on efficiencies created by AI, Bloomberg reportsTSMCis developing advanced AI chip packaging technology, internally called "EMIB-like," that is said to be similar to Intel'sEmbedded Multi-die Interconnect Bridge technique, The Information saysAmazonand Walmart'sshopping bots are sidelining "Made in USA" product data on their platforms, WSJ reportsThree years ago, Warner Bros. Discovery'sfilm "Barbie" racked up $1.5B in worldwide box office sales, the most for a Warner Bros.film, and now the company wants to get a sequel under production, NY Times saysSome Teslaexecutives have been instructed by Elon Musk to prepare for a separation of the company's China business in the event of a potential merger with SpaceX, WSJ reports4. MOVERS:AXT Inc.increases afterand providing guidance for Q3nVent Electrichigher in New York afterand listening additional manufacturing space in MinnesotaNewell Brandsand DexComgains in New York afterGoDaddyfalls after, providing guidance for Q3, and narrowing its outlook for FY26Cerusand Veracytelower after5. EARNINGS/GUIDANCE:AbbVie, cut its EPS guidance for FY26, and provided guidance for Q3RBC Bearings, with EPS and revenue beating consensusColgate-Palmolivewith CEO Noel Wallace commenting on "strong broad-based top- and bottom-line results, despite a difficult operating environment"Eaton, provided guidance for Q3, and raised its outlook for FY26Magnaand raised its outlook for FY26INDEXES:Near midday, the Dow was up 191.57, or 0.37%, to 52,399.63, the Nasdaq was up 67.77, or 0.27% to 25,189.95, and the S&P 500 was up 16.41, or 0.22%, to 7,454.04.
Veracyte Shares Drop 24% to $45.41
Veracyte is down -24.0%, or -$14.37 to $45.41.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.